Effects of Nonsteroidal Anti-Inflammatory Drugs on Experimental Allergic Conjunctivitis in Guinea Pigs

Journal of Ocular Pharmacology and Therapeutics

Volumn 19, Issue 6, 2003, Pages 569-577

  Hashimoto, Terumasa ^a,b   Igarashi, Atsushi ^a,b   Hoshina, Futoshi ^a,b   Yamada, Mie ^a,b   Toyoda, Yoshihiro ^a,b   Notsu, Yoshitada ^a,b   Kohno, Shigekatsu ^a,b  

^a Wakamoto Pharmaceutical Co Ltd   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BROMFENAC; BRONUCK; DICLOD; DICLOFENAC; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOTIFEN; KETOTIFEN FUMARATE; NONSTEROID ANTIINFLAMMATORY AGENT; OVALBUMIN; PRANOPROFEN; PROSTAGLANDIN D2; PROSTAGLANDIN E2;

ALLERGIC CONJUNCTIVITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; EXUDATE; GUINEA PIG; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRURITUS; SCRATCHING;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS; BENZOPHENONES; BENZOPYRANS; BROMOBENZENES; CONJUNCTIVITIS, ALLERGIC; DICLOFENAC; DINOPROSTONE; DISEASE MODELS, ANIMAL; EVANS BLUE; EXUDATES AND TRANSUDATES; EYE; GUINEA PIGS; HISTAMINE; HISTAMINE RELEASE; IMMUNIZATION; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; IRRIGATION; KETOTIFEN; MALE; OVALBUMIN; PROPIONIC ACIDS; PROSTAGLANDIN D2; PRURITUS;

EID: 0347363605     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/108076803322660486     Document Type: Article

References (22)

1. Cook, E.B., Stahl, J.L., Barney, N.P., and Graziano F.M. Ocular mast cells. Characterization in normal and disease states. Clin. Rev. Allergy Immunol. 20:243-268, 2001.
2. Bielory, L. Ocular allergy treatment. Clin. Rev. Allergy Immunol. 20:201-214, 2001.
3. 2 generation after activation of rat and human mast cells with anti-IgE. J. Immunol. 129:1627-1631, 1982.
4. 2. Invest. Ophthalmol. Vis. Sci. 31:138-146, 1990.
5. Proud, D., Sweet, J., Stein, P., Settipane, R.A., Kagey-Sobotka, A., Friedlaender, M.H., and Lichtenstein, L.M. Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen. J. Allergy Clin. Immunol. 85:896-905, 1990.
6. Discepola, M., Deschenes, J., and Abelson, M. Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in clinical model of allergic conjunctivitis. Acta Ophthalmol. Scand. Suppl. 228: 43-46, 1999.
7. Tauber, J., Raizman, M.B., Ostrov, C.S., Laibovitz, R.A., Abelson, M.B., Betts, J.G., Koester, J.M., Gill, D., and Schaich, L. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J. Ocul. Pharmacol. Ther. 14:137-145, 1998.
8. Levine, B.B., Chang, H., and Vaz, N.M. The production of hapten-specific reaginic antibodies in the guinea pig. J. Immunol. 106:28-33, 1971.
9. Katayama, S., Shionoya, H., and Ohtake, S. A new method for extraction of extravasated dye in the skin and influence of fasting stress on passive cutaneous anaphylaxis in guinea pigs and rats. Microbiol. Immunol. 22:89-101, 1978.
10. Woodward, D.F., Nieves, A.L., Spada, C.S., Williams, L.S., and Tuckett, R.P. Characterization of behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen. J. Pharmacol. Exp. Ther. 272:758-765, 1995.
11. Friedlaender, M. Overview of ocular allergy treatment. Curr. Allergy Asthma Rep. 1:375-379, 2001.
12. Kamei, C., Izushi, K., and Nakamura, S. Effects of certain antiallergic drugs on experimental conjunctivitis in guinea pigs. Biol. Pharm. Bull. 18:1518-1521, 1995.
13. Okayama, Y., and Church, M.K. Comparison of the modulatory effect of ketotifen, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells. Int. Arch. Allergy Immunol. 97:216-225, 1992.
14. Peters, S.P., Naclerio, R.M., Schleimer, R.P., MacGlashan, D.W. Jr, Pipkorn, U., and Lichtenstein, L.M. The pharmacologic control of mediator release human basophils and mast cells. Respiration 50(suppl. 2):116-122, 1986.
15. Arimura, A., Yasui, K., Kishino, J., Asanuma, F., Hasegawa, H., Kakudo, S., Ohtani, M., and Arita, H. Prevention of allergic inflammation by novel prostaglandin receptor antagonist, S-5751. J. Pharmacol. Exp. Ther. 298:411-419, 2001.
16. 2 in greyhounds. Aust. Vet. J. 70:21-24, 1993.
17. Greaves, M.W., and Wall, P.D. Pathophysiology of itching. Lancet 348:938-940, 1996.
18. Woodward, D.F., Nieves, A.L., Hawley, S.B., Joseph, R. Merlino, G.F., and Spada, C.S. The pruritogenic and inflammatory effects of prostanoids in the conjunctiva. J. Ocul. Pharmacol. Ther. 11:339-347, 1995.
19. Woodward, D.F., Nieves, A.L., and Friedlaender, M.H. Characterization of receptor subtypes involved in prostanoid-induced conjunctival pruritus and their role in mediating allergic conjunctival itching. J. Pharmacol. Exp. Ther. 279:137-142, 1996.
20. 2. Acta Derm. Venereol. 57:37-43, 1977.
21. Sharma, A., Gupta, R., Ram, J., and Gupta, A. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J. Ophthalmol. 45:177-180, 1997.
22. Ciprandi, G., Buscaglia, S., and Cerqueti, P.M. Drug treatment of allergic conjunctivitis. Drugs 43:154-176, 1992.